ReviewFrontiers in immunology2020
Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Engineering cytokines for cancer immunotherapy: a systematic review.Frontiers in immunology · 2023Pooled it
- Interleukin-15 responses to acute and chronic exercise in adults: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- PEG-RLI: A Long-Acting IL-15 Agonist That Produces Massive Levels of CD8Pharmaceutics · 2026Article
- Cytokine Engineering in CAR-T Cell Therapy: Next-Generation Strategies.Immune network · 2025Review
- Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors.Cell reports. Medicine · 2025Article
- A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer.Cancer immunology research · 2025Article
- Signaling intact membrane-bound IL-15 enables potent anti-tumor activity and safety of CAR-NK cells.Frontiers in immunology · 2025Article
- Nanoenabled IL-15 Superagonist via Conditionally Stabilized Protein-Protein Interactions Eradicates Solid Tumors by Precise Immunomodulation.Journal of the American Chemical Society · 2024Article
- Article
- GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the Treatment of TA-MUC1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution Studies.International journal of molecular sciences · 2024Article
- Leveraging long-acting IL-15 agonists for intratumoral delivery and enhanced antimetastatic activity.Frontiers in immunology · 2024Article
- Research Hotspots and Trends in Global Cancer immunometabolism:A Bibliometric Analysis from 2000 to 2023.Journal of multidisciplinary healthcare · 2024Review
- A Self-Activating IL-15 Chimeric Cytokine Receptor to Empower Cancer Immunotherapy.ImmunoTargets and therapy · 2024Article
- Multimeric immunotherapeutic complexes activating natural killer cells towards HIV-1 cure.Journal of translational medicine · 2023Article
- First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.Journal for immunotherapy of cancer · 2023Article
- Immunomodulation with IL-7 and IL-15 in HIV-1 infection.Journal of virus eradication · 2023Article
- A mathematical model of protein subunits COVID-19 vaccines.Mathematical biosciences · 2023Article
- Review
- INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses.Journal for immunotherapy of cancer · 2023Article
- Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-15 (IL-15) is crucial for the proliferation and survival of NK and CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.